Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Haloperidol for agitation in dementia.

E Lonergan1, J Luxenberg, J Colford

  • 1Department of Medicine, UCSF School of Medicine, VA Medical Center, 4150 Clement St, San Francisco, California 94121, USA. tedlnrgn@aol.com edmund.lonergan@med.va.gov

The Cochrane Database of Systematic Reviews
|November 1, 2001
PubMed
Summary

Haloperidol did not improve agitation in dementia patients compared to placebo, though it may help aggression. Side effects and dropouts were more frequent with haloperidol, limiting treatment recommendations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence supporting the use of a brief cognitive assessment in routine clinical assessment for psychosis.

Schizophrenia (Heidelberg, Germany)·2022
Same author

Deathbed wills: assessing testamentary capacity in the dying patient.

International psychogeriatrics·2013
Same author

The wills of older people: risk factors for undue influence.

International psychogeriatrics·2008
Same author

Antipsychotics for delirium.

The Cochrane database of systematic reviews·2007
Same author

Valproic acid for agitation in dementia.

The Cochrane database of systematic reviews·2004
Same author

Transcutaneous electrical nerve stimulation (TENS) for dementia.

The Cochrane database of systematic reviews·2003

Area of Science:

  • Geriatric Medicine
  • Psychopharmacology
  • Dementia Care

Background:

  • Agitation, including wandering and aggression, affects up to 70% of dementia patients.
  • Haloperidol, a neuroleptic, is used for disruptive behaviors but its effectiveness in agitated dementia is debated.
  • Previous meta-analyses had limitations in scope and databases, necessitating a focused review.

Purpose of the Study:

  • To determine if evidence supports haloperidol's use for treating agitation in demented patients.
  • To provide recommendations for future research in this area.

Main Methods:

  • Systematic review and meta-analysis of randomized, placebo-controlled trials.
  • Inclusion criteria: concealed allocation, assessed dementia and agitation, treatment duration over one week.

Related Experiment Videos

  • Data extraction and analysis included intention-to-treat data, odds ratios, and sensitivity analysis for heterogeneity.

    • Main Results:

    • Five trials were included; overall meta-analysis showed no improvement in agitation with haloperidol versus placebo.
    • Some evidence suggests haloperidol may help control aggression, but adverse reactions and dropouts were more frequent.
    • Higher doses or prolonged therapy (over 12 weeks) were associated with increased side effects, particularly Parkinsonian symptoms.

    Conclusions:

    • Haloperidol offers no significant improvement for agitation in dementia patients, and is associated with frequent side effects and higher dropout rates.
    • Limited information prevents specific recommendations regarding dementia severity, agitation type, or optimal haloperidol dosage/duration.
    • While higher doses may aid aggression control, prolonged use or higher doses increase side effect risk, suggesting cautious use.